Extended Data Fig. 12: Anti-progestins block stiffness-induced SOX9 and C-KIT.
From: Anti-progestin therapy targets hallmarks of breast cancer risk
A-B) C-KIT and SOX9 protein detection in normal breast microstructures cultured in collagen-mimetic hydrogels under ‘soft’ (S) and ‘stiff’ (ST) conditions, treated for 7 days with: A) Ulipristal Acetate (UA, 2 nM), or B) Onapristone (ON, 100 nM). β-actin was used as a reference for the loading control. Densitometry quantification, normalised to β-actin, is shown at the top of each band. N = 3 breast samples. C) Heatmap from whole tissue RNA-Seq gene expression analysis showing all the differentially expressed genes between high MD (BI-RADS C/D, dark grey) and low MD (BI-RADS A/B, light grey) breast tissue at BC-APPS1 baseline (n = 9; p < 0.05). VST - Variance Stabilising Transformation. D) Correlation (two-sided test) between VBD percentage and gene expression of CXCL13 and TNFSF11 in baseline breast tissue of BC-APPS1 participants. N = 9 baseline tissue.
